Table 2.

Key definitions of BCG-unresponsive non-muscle invasive bladder cancer and adequate BCG treatment

BCG-unresponsive non-muscle invasive bladder cancer

• Persistent or recurrent CIS alone or with Ta/T1 disease within 12 months of adequate BCG therapy   • Recurrent high-grade Ta/T1 disease within 6 months of completion of adequate BCG therapy   • T1 high-grade disease on the first evaluation following an induction BCG course

Adequate BCG treatment

• At least five of six doses of the initial induction course and at least two of three doses of the maintenance treatment   • At least five of six doses of the initial induction course and at least two of six doses of the second induction course